| Filed On | Filing |
|---|---|
| 15 Nov 2024 |
8-K: Completion of Acquisition or Disposition of Assets; Notice of Delisting or Failure to Satisfy a Listing Rule +4 more
Section 1. ANNUAL MEETING. The annual meeting of the stockholders of Axonics, Inc. (the “Corporation”), for the purpose of electing directors and for the transaction of such other business as may be brought before the meeting, shall be h... |
| 07 Nov 2024 |
8-K: Results of Operations and Financial Condition
IRVINE, Calif. – November 7, 2024 – Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops, manufactures and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today report... |
| 01 Aug 2024 |
8-K: Results of Operations and Financial Condition
Generated record revenue, gross margin and net income in 2Q24 |
| 30 Apr 2024 |
8-K: Results of Operations and Financial Condition
IRVINE, Calif. – April 30, 2024 – Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial res... |
| 04 Apr 2024 |
8-K: Other Events
As previously disclosed, on January 8, 2024, Axonics, Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Boston Scientific Corporation, a Delaware corporation (“Boston... |
| 25 Mar 2024 |
8-K: Submission of Matters to a Vote of Security Holders; Other Events
IRVINE, Calif – (BUSINESS WIRE) – Axonics, Inc. (Nasdaq: AXNX) announced that its stockholders have voted today to adopt Axonics’ merger agreement with Boston Scientific Corporation (NYSE: BSX). According to preliminary voting results fr... |
| 28 Feb 2024 |
8-K: Results of Operations and Financial Condition
IRVINE, Calif – (BUSINESS WIRE) – Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial result... |
| 08 Jan 2024 |
8-K: Entry into a Material Definitive Agreement; Departure/Election of Directors or Officers; Compensation
Exhibit A – Second Amended and Restated Certificate of Incorporation of the Surviving Corporation |
| 08 Jan 2024 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
IRVINE, Calif – (BUSINESS WIRE) – Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported preliminary unau... |
| 30 Oct 2023 |
8-K: Results of Operations and Financial Condition
Generated quarterly revenue of $93.1 million, an increase of 32% year over year |
| 04 Oct 2023 |
8-K: Departure/Election of Directors or Officers; Compensation
This Executive Employment Agreement (this “Agreement”) is dated as of October 2, 2023 by and between Axonics, Inc., a Delaware corporation (the “Company”), and Raymond W. Cohen (“Executive”). |
| 21 Aug 2023 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
IRVINE, Calif. – August 21, 2023 – Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that Dan L. De... |
| 27 Jul 2023 |
8-K: Results of Operations and Financial Condition
Generated quarterly revenue of $92.9 million, an increase of 35% year over year |
| 27 Jun 2023 |
8-K: Submission of Matters to a Vote of Security Holders
Axonics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”) on June 26, 2023. On April 27, 2023, the record date (the “Record Date”) for determining stockholders entitled to vote at the Annual Meeting, th... |
| 18 May 2023 |
8-K: Other Events
We have acted as counsel to Axonics, Inc., a Delaware corporation (the “Company”), in connection with the Registration Statement on Form S-3 (No. 333-271663) (the “Registration Statement”) filed by the Company with the Securities and Exc... |
| 01 May 2023 |
8-K: Results of Operations and Financial Condition
Generated quarterly revenue of $70.7 million, an increase of 46% year over year |
| 06 Apr 2023 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +1 more
THIS LEASE is made as of April 1, 2023, by and between SAND CANYON BUSINESS CENTER I LLC, a Delaware limited liability company, hereafter called “Landlord,” and AXONICS, INC., a Delaware corporation, hereafter called “Tenant.” |
| 01 Mar 2023 |
8-K: Results of Operations and Financial Condition
Generated record quarterly revenue of $86 million, an increase of 62% y/y |
| 11 Jan 2023 |
8-K: Results of Operations and Financial Condition
4Q22 total company net revenue expected to be $85.6 to $86.0 million, an increase of 61% y/y |
| 31 Oct 2022 |
8-K: Results of Operations and Financial Condition
IRVINE, Calif. – October 31, 2022 – Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial resu... |
Loading...